MBCProject_0054_T1B_RNA
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.370
- INTERFERON_ALPHA_RESPONSE+0.360
- MITOTIC_SPINDLE+0.350
- TNFA_SIGNALING_VIA_NFKB+0.310
- G2M_CHECKPOINT+0.240
- PROTEIN_SECRETION+0.230
- UNFOLDED_PROTEIN_RESPONSE+0.230
- PI3K_AKT_MTOR_SIGNALING+0.180
- IL6_JAK_STAT3_SIGNALING+0.160
- ANDROGEN_RESPONSE+0.150
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.420
- COAGULATION-0.400
- ANGIOGENESIS-0.370
- NOTCH_SIGNALING-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.330
- ADIPOGENESIS-0.290
- FATTY_ACID_METABOLISM-0.280
- XENOBIOTIC_METABOLISM-0.280
- GLYCOLYSIS-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_0054_T1A_RNA | — | A | 0.868 |
| 2 | AUR-AFSO-TTP1-A-8-0-R-A741-41 | — | C | 0.775 |
| 3 | SRR2016974 | — | — | 0.772 |
| 4 | SRR6013475 | — | cohortMD2 | 0.765 |
| 5 | SRR10899995 | — | — | 0.756 |
| 6 | SRR8942978 | — | — | 0.754 |
| 7 | SRR2016949 | — | — | 0.744 |
| 8 | ERR4976616 | — | C | 0.741 |
| 9 | AUR-AFE5-TTP1-A-1-0-R-A741-41 | — | D | 0.736 |
| 10 | SRR8518162 | — | E | 0.734 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.130 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.110 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.020 | Idelalisib | — uncovered |